Series A

Techstars' exclusive partnership with Xendoo and Xero signals a new era of strict financial discipline for startups, driven by AI and investor demands.

A new platform launches to connect accessible tech startups with users and investors, aiming to unify a fragmented but powerful innovation ecosystem.

A new benchmark shows top AI voice tools fail in non-English languages, challenging billion-dollar deployments and exposing deep-rooted linguistic bias.

By rethinking a 50-year-old component, Aqua Membranes is poised to revolutionize water treatment and contend for the $119M XPRIZE Water Scarcity prize.

As its oesophageal cancer vaccine enters trials, Infinitopes hires a top CSO with a track record of bringing breakthrough therapies to market.

As investors flee to gold, a new report highlights top IRA providers. But what are the real risks and rewards of moving your 401k into precious metals?

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

As it nears $10B in assets, investment firm Disruptive hires a top tech advisor, signaling a new phase of strategic growth for its unique investment model.

Forethought founder Deon Nicholas unveils Espa, an AI executive assistant that executes tasks, aiming to democratize productivity for all.

Fueled by a $100M R&D investment, Chinese beauty giant Yatsen is leading a market shift from price wars to scientific innovation, winning global consumers.

As climate impacts escalate, investors are shifting focus from emissions to adaptation, funding startups that fortify our grid, water, and food systems.

Three industry titans launch AlphaDrive, a $100M fund blending VC and private equity to back the next generation of Israeli Cyber-AI startups.

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

The biopharma firm gets a significant non-dilutive cash infusion, bolstering its finances to advance a promising oncology pipeline without equity dilution.

UTime's latest capital raise is a fraction of its needs. We dive into the firm's mounting losses, stock dilution, and what this means for its future.

With new FDA clearance, Zeta Surgical's portable AI navigation system could bring millimeter-precision brain surgery to any hospital, not just elite centers.

Medcura adds a Johnson & Johnson heavyweight to its board, aiming to disrupt the surgical hemostasis market with its FDA-designated breakthrough gel, LifeGel.

AI-native firm Norm Law adds veteran tax and fund formation counsel, deepening its tech-driven challenge to the traditional legal services model for investors.